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ABSTRACT 
The aim of this study was to prepare and evaluate gels 
incorporating solid lipid nanoparticles (SLNs) of 
diclofenac sodium for systemic delivery of the active 
after topical application. SLNs were prepared using hot 
homogenization followed by sonication technique and 
these were incorporated into freshly prepared carbopol 
gel. Three different gel formulations (DSL1, DSL2 and 
DSL3) were prepared and characterized for particle size, 
charge, viscosity, morphology, and drug-lipid 
compatibility. The gels were evaluated for in vitro drug 
release, ex vivo permeation studies and in vivo 
absorption. The gels enriched with SLN sustained the 
drug release for 24 h both in vitro and in vivo. The 
results suggest enhancement in systemic delivery of 
diclofenac sodium with gels incorporating SLNs.  
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Diclofenac Sodium (DS) is widely used for 
antirheumatic, analgesic, osteoarthritis, and antipyretic 
activities [1]. It is currently popular to treat the 
aforementioned first three ailments using a topical 
formulation. However, oral diclofenac is still popular 
despite the side-effects, especially for certain conditions 
and also for its antipyretic activity. The most common 
adverse effects of the drug after oral administration are 
gastritis, peptic ulceration, and depression of renal 
functions. Additionally, it also has short biological half-
life which forces higher doses for oral administration, 
further increasing its GIT side-effects. Because of these 
disadvantages of oral diclofenac, topical diclofenac has 
been investigated very early on and now several 
successful formulations are available in the market [2]. 
However, for certain ailments where in diclofenac is 
useful topical route is not preferred. The drug should be 
systemically available. For this purpose, the drug was 
either given by intravenous route or oral route [3]. Oral 
route is disadvantageous as mentioned previously while 
intravenous route is less patient compliant. Thus, this 
study aims to investigate the systemic delivery of 
diclofenac after topical administration. Topical semi-
solids for systemic delivery of drugs is also the state of 
art research in topical formulations [4,5].  Previous 
studies indicate that diclofenac sodium reaches systemic 
circulation after topical administration [6]. This suggests 
that topical semisolids for systemic delivery of 
diclofenac is a viable option. In this study, a novel gel 
incorporating SLNs taking the advantage of effective 
skin penetration using solid lipid nanoparticles was used 
to demonstrate better systemic delivery of diclofenac 
compared to conventional semi-solid formulations. SLN 
formulations previously demonstrated to aid in better 
skin penetration of the active after topical administration.   
 
The main challenge in systemic drug delivery 
via topical route is to overcome the inherent barrier of the 
skin. The rate-limiting step in transdermal transport 
generally occurs at the stratum corneum, the outermost 
layer of the skin. Many approaches have been used to 
enhance the penetration of drugs though this layer of the 
skin. SLN approach is also one among them [7, 8]. The 
small particle size ensures close contact with the stratum 
corneum and increases the amount of encapsulated 
compounds penetrating into the skin [9, 10, 11]. 
Moreover, SLNs have distinct occlusive properties due to 
the formation of an intact film on the skin surface upon 
drying, which decreases transepidermal water loss and 
favours the drug penetrating though the stratum corneum 
[12, 13]. The nanometer sized particles can make close 
contact with superficial junctions of corneocyte clusters 
and furrows between corneocyte islands, which may 
favour accumulation for several hours allowing for 
sustained drug release [14, 15]. The advantages of the 
carrier include negligible skin irritation, controlled 
release, and protection of active substances [16]. Because 
they are composed of non-irritative and non-toxic lipids, 
SLNs seem to be well suited for use on inflamed and 
damaged skin. However, SLN suspension has very low 
viscosity; therefore, it is not convenient for use on the 
skin. An alternative i.e., incorporation of SLN into gels 
and further their administration topically has been 
suggested and investigated [8, 17, 18]. In this study a 
carbopol gel which is a hydrogel was used as a vehicle 
for SLN to achieve systemic delivery of diclofenac 
sodium after topical administration. Hydrogels are 
clinically acceptable systems that offer many advantages, 
such as suitable rheological properties, good tissue 
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compatibility and convenience in handing and ease of 
application [19]. Carbopol gels incorporating diclofenac 
sodium loaded SLN formulations were prepared and 
evaluated. Furthermore, to demonstrate the systemic 
penetration of the drug, an ex vivo permeation with rat 
skin and a pharmacodynamic study to evaluate its anti-
inflammatory activity using a carrageenan-induced rat 
paw edema model for the gel formulations were 
investigated. 
 
Materials and methods 
Materials 
Diclofenac Sodium(DS) was obtained from Alkha 
pharmaceuticals (Hyderabad, India), Dynasan 116 was 
purchased from Sigma Aldrich (Mumbai, India). 
Carbopol 934 was purchased from Genuine Chemical co. 
(Mumbai, India). Chloroform and methanol were 
purchased from Finar chemicals (Ahmedabad, India).  
Acetonitrile (HPLC grade) was procured from Merck 
specialities (New Delhi, India). Centrisart filters 
(molecular weight cutoff 20,000) were purchased from 
Sartorious Stedim Biotech (Bangalore, India). Propylene 
glycol and tween 80 were purchased from Qualikems 
fine Chemicals (Mumbai, India). Soyalecithin was 
purchased from Hi-media (Mumbai, India). Carrageenan 
was procured from SD fine chemicals.  The other 
chemicals were of analytical grade. 
 
 
Preparation of SLNs of Diclofenac Sodium 
To prepare SLNs, DS, dynasan 116, and 
phosphatidylcholine of different compositions (Table 1) 
were dissolved in 10 ml mixture of chloroform and 
methanol (8:2). Organic solvents were completely 
removed using a rotoevaporator (Laborota 4000, 
Heidolph, Germany) to form a drug-embeded lipid layer. 
This layer was melted by heating at 65°C above the 
melting point of the lipid. Aqueous phase was prepared 
by dissolving polysorbate 80 (2 % w/v) in double 
distilled water (10 ml) and heated to same temperature of 
oil phase. Hot aqueous phase was added to the oil phase, 
and homogenization was carried out (at 8000 rpm and 
temperature 70°C) using a REMI homogenizer (Mumbai, 
India) for 3 min. Coarse hot oil in water emulsion so 
obtained was ultrasonicated (150V/T probe) using a 
ultrahomogenizer (Biologics inc., USA) for 15 min. 
Diclofenac Sodium solid lipid nanoparticles were 
obtained by allowing hot nanoemulsion to cool to room 
temperature. This results in the formation of DS SNLs 
used in the preparation of DSL1, DSL2 and DSL3 gels.   
 
 
Table 1. Composition of the investigated DSSLN (wt. %) 
Formulations DS Dynasan 116 Soyalecithin Tween 80 Water 
DSL1 0.25 3 1 2 93.75 
DSL2 0.50 3 1 2 93.50 




Preparation and Characterization of DS SLN gel 
To prepare carbopol gel, carbopol 934 (1 g) 
was dispersed in demineralised water (88 ml) by stirring 
at 800 rpm (Remi, Mumbai, India) for 60 minutes. Then, 
propylene glycol (10 ml) was added and the mixture was 
neutralised by drop wise addition of 10% NaOH. Mixing 
was continued until a transparent gel appeared, while the 
amount of the base was adjusted to achieve a gel with pH 
6.5. To prepare, DS SLN gel, aqueous DS SLN 
dispersions and carbopol hydrogel were mixed in a high 
speed stirrer (Remi, Mumbai, India) at approximately 
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1000 rpm for 5 min. The gel to SLN ratio was such that a 
50% SLN was present in the gel.  
 
The SLN enriched hydrogels were 
characterized for their physicochemical properties such 
as colour, odour and pH. The mean size and 
polydispersity index of the size distribution and zeta 
potential of SLN were determined using photon 
correlation spectroscopy (PCS) using Zetasizer 3000 
HAS (Malvern Instruments, Malvern, UK). Briefly, the 
SLN dispersions were diluted 1:1000 with the aqueous 
phase of the formulation to get a suitable kilo counts per 
second (kcps). Analysis was performed at 25°C with an 
angle of detection of 90°.  Entrapment Efficiency (EE) 
was determined by measuring the concentration of free 
drug (unentrapped) in aqueous medium as reported 
previously [20]. The diluted aqueous medium containing 
the DS SLN gel was subjected to ultra-filtration to 
separate the free drug from encapsulated drug.  Centrisart 
tubes, which consists of filter membrane (M.wt. cut off 
20,000 Da) at the base of the sample recovery chamber 
was used. About 1ml of the diluted formulation was 
placed in the outer chamber and sample recovery 
chamber was placed on top of the sample and centrifuged 
at 4000 rpm for 15 min. The formulation was diluted to 
1000 times using the same buffer used in the preparation 
of the gels. The SLN along with encapsulated drug 
remained in the outer chamber while the aqueous phase 
moved into the sample recovery chamber through filter 
membrane. The amount of DS in the aqueous phase was 
estimated using a HPLC method previously described. A 
Cyberlab-Chrom HPLC system (cyberlabs, USA) was 
used for the purpose. The column used was C18 ODS 
column and the size of silica used in this column is 5μm 
and the dimensions of the column is 4.6 × 250mm. 
Mobile phase consisted of acetonitrile/distilled 
water/acetic acid (40:60:2) while the peak detection was 
measured at 276 nm. An injection volume of 20 µl and a 
flow rate of 1.1 ml/min were used, and diclofenac 
sodium could be detected at a retention time of 8.2 min 
and a wavelength of 276 nm. The data was recorded 
using ws-100 Workstation software. The entrapment 
efficiency was calculated by the equation: 
 
 
  Wt. of drug used in the formulation − Wt. of drug in aqueous phase    × 100 
 EE (%) =              




To predict if there is any drug-lipid interaction, DS, 
dynasan 116, soya lecithin and DS SLN were subjected 
to FTIR analysis. The morphology of DS loaded SLNs in 
the gels was examined by scanning electron microscope 
(SEM). 
 
In vitro drug release studies were performed in 
vertical Franz diffusion cell. Phosphate buffer pH 7.4 (24 
ml) was placed in the receiver compartment. A 0.5 gm of 
SLN gel of diclofenac was placed in the donor 
compartment. A dialysis membrane was used to separate 
the donor and receiver compartments.  The diffusion 
cells were maintained at (37±0.5ºC) with stirring at 
600rpm through out the experiment. At fixed time 
intervals, 5 ml of the sample was withdrawn from 
receiver compartment though side tube and analyzed by 
UV-Visible spectrophotometer at 276nm. Data obtained 
from in vitro release studies were fitted to various kinetic 
equations to find out the mechanism of diclofenac release 
from SLN gel. The kinetic models used were zero order 
equation, Higuchi release and Korsemeyer-Peppas. 
 
The rheology of prepared gels was determined 
using a rheometer Brookfield Programmable Rheometer 
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LVDV-III + CP 230 equipped with a cone and plate test 
geometry (plate diameter 20 mm, cone angle 4°). All 
measurements were carried out at a temperature of 20 ± 
0.1°C. The rheological properties of the developed 
hydrogels containing SLN were studied by continuous 
shear investigations, which were performed in order to 
evaluate the shear rate [1/s] as a function of shear stress 
[Pa]. This study started applying 0 Pa up to a maximum 





Male Wister rats (150-200 gm) purchased from the 
Mahaveer enterprises (Hyderabad, India) were used in 
the animal studies. The animals were kept under standard 
laboratory conditions, at 25 ± 10C and 55 ± 5% relative 
humidity with a 12 h light/dark cycle. The animals were 
housed in polypropylene cages, with free access to a 
standard laboratory diet and water. All surgical and 
experimental procedures were reviewed and approved by 
the animal and ethics review committee, Vaagdevi 
College of Pharmacy, Warangal, Andhra Pradesh, India. 
Ex Vivo drug permeation studies as well as 
pharmacodynamic studies were conducted using rats.  
 
Ex Vivo Permeation Studies 
Skin from the abdominal region was excised 
after hair was removed with a depilatory, and examined 
for integrity using a lamp-inspecting method. The 
subcutaneous fat and connective tissue were carefully 
removed. The obtained skin was rinsed with 
physiological saline and further used to study drug 
permeation. A system employing vertical Franz diffusion 
cells with a diffusional area of 4.15 cm2 was used for 
permeation studies. The excised rat skin was set in place 
with the stratum corneum facing the donor compartment 
and the dermis facing the receiver compartment. A 0.5 
gm of the gel containing DS or DS SLN was applied to 
the skin surface in the donor compartment and the 
receptor compartment of the cell was filled with 24 ml of 
phosphate buffer (pH 7.4). During the experiments, the 
diffusion cell was maintained at 37 ± 0.5°C and stirred at 
600rpm. After application of the test formulation on the 
donor side, 5 ml aliquots were collected from the receiver 
compartment at designated time intervals (1, 2, 4, 8, 12, 
and 24 h). Each time after the sample was removed from 
the receiver, an equivalent volume of buffer was supplied 
to the receiver compartment. The collected samples were 
analysed by UV-Vis spectrophotometer at 276nm. The 
amount of diclofenac released was determined from a 
standard curve generated using UV-Vis 




Carrageenan induced paw edema method was 
used to study the in vivo performance of the prepared 
drug delivery system. Anti-inflammatory activity was 
determined by measuring change in the volume of 
inflamed paw, produced by injection of carrageenan (0.1 
ml of 1% w/v) using plethysmometer (INCO, India). 
Male wister rats selected for the study were weighed and 
marks were made on the right hind paw just behind tibia-
tarsal junction on each animal. To ensure constant paw 
volume, every time the paw was dipped in the 
plethysmograph (mercury displacement method) up to 
the fixed mark. Rats were divided into four groups 
including one controlled group with each group 
comprising of 3 animals. The control group received 
normal saline orally. The other three groups received oral 
diclofenac, diclofenac carbopol gel and DSL3. 
Diclofenac gel was prepared as the DSLs were prepared, 
excepting the drug was added as a dispersion in the gel. 
DSL3 was used in the antiinflammatory studies because 
of higher drug release and higher drug permeation when 
compared to other two formulations (Figure 3 and Figure 
4). Oral diclofenac was given in the form of suspension 
made in sodium CMC. The drug in all the three 
formulations was equal and was 5 mg. The paw volume 
was noted at 0, 1, 2, 4, 6, 8, 12 and 24 h. 
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The formulation was applied transdermally to 
the abdomen of albino rats of respective groups, 
excluding the animals of controlled group. After 30 min 
of transdermal application or oral administration of 
formulations, 0.1 ml of 1% w/v carrageenan (in 0.9% 
normal saline) was injected in the sub planter region of 
the right hind paw of rats. The initial reading just after 
injection and subsequent paw volumes was measured up 
to 24 h. The percent inhibition of edema induced by 
carrageenan was calculated for each group using the 
following equation [22]: 
 
% inhibition of edema = 100(1- (a-x/b-y))  
 
Where a = mean paw volume of treated animals after 
carrageenan injection  
x = mean paw volume of treated animals 
before carrageenan injection  
 b = mean paw volume of control animals after 
carrageenan injection  




Results and Discussion 
 
 
For the current study, three batches of SLNs were 
successfully prepared and the composition of the 
formulations prepared is shown in Table 1. And these 
SLN formulations were successfully incorporated into 
carbopol gel; it was prepared using a optimal stabilizer 
combination of water, carbopol and propylene glycol as 
hydrating agent. The DSSLN dispersions were white in 
colour, odourless and fluid in nature. Gels loaded with 
DSSLN dispersions were colourless, odourless with 
smooth appearance. The SEM image of DSSLN 
dispersion was presented in Figure 1. The figure shows 
that the particles were spherical in shape. The 
Entrapment Efficiency values were determined for three 
formulations and observed as 60%±0.545, 54%±0.62 and 
50%±0.75 for DSL1, DSL2 andDSL3, respectively. The 
reports revealed by the FTIR study confers that there is 
no interaction between the lipids and drug (data not 
shown). Particle size, polydispersity index (PDI) and 
Zeta potential values of the formulation DSL3 in 
carbopol gel was found to be 158.1±9.2 nm, 0.273±0.032 
and -35.9±2.66 respectively (mean±S.D (n=3)). DSL3 
formulation was the final formulation selected for the 





                                           
Fig. 1. SEM photograph of diclofenac loaded solid 
lipid nanoparticles 
 
The rheological status of a semisolid drug carrier system 
is a very important physical parameter. Rheology 
measurements provide essential information about 
different aspects concerning semisolid preparations. 
Rheological properties therefore affect all stages of 
manufacture like mixing, pumping, filling etc. Moreover, 
rheological measurements are valuable tools in quality 
control of ingredients and final products. Concerning 
application and performance on skin they provide 
essential information. Furthermore, drug release from 
semisolid vehicles is influenced by the rheological 
behaviour. The rheological behaviour of hydrogels 
loaded with SLN was evaluated after 1 week of storage at 
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room temperature. The flow curves of the gels are shown 

























Fig. 2. Shear rates of SLN containing hydrogels as a 
function of shear stress, measured after 7 days of 
storage at room temperature.  
 
The cumulative amount release of DS from DSL1, 
DSL2, DSL3 gels were investigated for a period of 24 h. 
Figure 3 shows the in vitro release profile of DSSLN 
gels.  DSL1, DSL2, DSL3 (DSSLN-gel) could prolong 
the drug release by the fact that the drug molecules are 
entrapped in the solid lipid matrix. The amount of drug 
release at the end of 24 h in DSL1, DSL2 and DSL3 
(DSSLN) gel formulations was found to 0.88, 1.52 and 
2.21 mg, respectively. A different release kinetic was 
observed for the SLN dispersions and SLN gel 
formulations. Fick's law of diffusion seems not to be 
applicable in each case. All the SLNs enriched gel 
formulations showed controlled drug release and also an 
increase in release rate was observed after 24 h. The log 
percent cumulative drug released was plotted as a 
function of log time and the slope of the curves was 
determined as the values of diffusional release exponent 
(η). The values of diffusional release exponent (η) from 
the straight lines were noted to be 0.79, 0.78 and 0.69 in 
SLN gel formulations of DSL1, DSL2 and DSL3 
respectively, which showed that the release of drug from 
formulations followed a non-Fickian pattern [23]. From 
the cumulative amount drug released versus time plot, 
the slope values were determined as release rate 
constants. The release rate constants were 0.038, 0.0618 
and 0.089 mg/cm2/h for DSL1, DSL2 and DSL3 gel, 
formulations respectively. Thus, the formulations with 
higher drug content shows higher release rate constants. 
The slower release of drug from SLN enriched carbopol 
gel maintained the drug concentration for longer period 
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Fig. 3.  In vitro release of DS from gels enriched with 
















































Fig. 4.  In vitro permeation of DS from gels enriched 
with SLN dispersions, Mean S.D (n = 3) 
 
The cumulative amount permeated of DS from DSL1, 
DSL2, DSL3 gels were investigated for a period of 24 h. 
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Figure 4 shows the in vitro permeation profile of DSSLN 
gels of DSL1, DSL2, DSL3 (DSSLN-gel). Cumulative 
amount of drug permeated in 24 h were 233.33, 289.23 
and 336.93 µg/cm2 for DSL1, DSL2 and DSL3 (DSSLN-
gel) formulations respectively. The release kinetics was 
established by determining the diffusional release 
exponent from the plot of log of cumulative drug 
permeated versus log time. This plot yielded a straight 
line from which diffusional release exponent (η) were 
calculated and found to be 0.41, 0.46 and 0.40 in  SLN 
gel formulations of DSL1, DSL2 and DSL3, 
respectively.  The results indicate that permeation of drug 
from these formulations followed a Fickian pattern [23]. 
A lag time (15min–1h) was observed in DSL1 and DSL2 
SLN gel formulations. This could be because in these 
formulations the drug has to cross two diffusion barriers, 
one the gel and the other is skin. No lag time was 
observed with DSL3 gel formulation. This could be 
because of higher amount of drug available. The SLN 
enriched gel formulations possessed a sustained drug 
release over a period of 24 h period. From the cumulative 
drug permeated versus time plot, the slope values were 
determined and these are considered as the skin 
permeation rates. The permeation rate constants were 
found to be 8.83, 11.14 and 12.43 µg/cm2/h. The slower 
release of drug from SLN carbopol gels maintained the 
drug concentration for longer period of time. The results 
of this study indicate that significant diclofenac travels 
across the skin and there could be likely systemic 
delivery of diclofenac from these formulations after 
topical administration. To corroborate the fact, a study to 
investigate systemic delivery in live animals was 
conducted. The formulation DSL3 which demonstrated 
good in vitro release as well as in vitro permeation was 





































Fig. 5.f Anti-inflammatory activity of diclofenac 
sodium SLN  enriched hydrogels after transdermal 
application in comparison to oral administration and 
diclofenac sodium  gel in carrageenan induced rat 
paw oedema (n = 3) 
 
 
The in vivo performance of selected DSL3 (DSSLN) 
enriched hydrogel was evaluated in a carrageenan- 
induced rat paw edema model (Figure 5). Formulations 
DSL3 under study not only decreased the inflammation 
to the larger magnitude, but also sustained this 
magnitude. In DSL3 formulation the maximum inhibition 
was observed at 8th h with higher value (70%), and even 
after 24 h, 46% inhibition was observed.  However, in 
case oral administration, inhibition was displayed at 1 h 
with magnitude of 99.5% and just after 4 h it scored 
below 65% and in case DS gel administration, inhibition 
was displayed at 2 h with magnitude of 68% and just 
after 6 h it scored below 36 % (Figure 5). There are is a 
sharp rise in the activity with oral administration. This 
can be explained because significant drug concentrations 
might have reached the systemic circulation after oral 
administration and the activity also subsided quickly. 
This is because of the short half-life of the drug. Also the 
inhibition when compared to topical formulations was 
very high. The dose administration in all the cases is the 
same. This indicates that the drug reaches the target 
tissue quickly from the systemic circulation. On the other 
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hand, the gel formulations although demonstrated a 
profound antiinflammatory activity, it was considerably 
lower than oral administration. This suggests that drug 
reaches the systemic circulation after topical 
administration. Interestingly, the effect with DSL3 is 
sustained. The possible reason could be the drug 
concentration in the blood, which was maintained for 
longer duration in case of formulation DSL3 in 
comparison to the drug administered orally and gel form. 
Thus, in comparison to orally administered DS and DS 
gel, the formulations DSL3 which was applied 
transdermally gave good results. The maximum 
inhibition for DSL3 was observed at 8 h and the 
inhibition was maintained up to 12 h and also even after 
24 h inhibition was observed. The anti-inflammatory 
activity of the formulation (DSL3) was maintained for 
longer period of time due to slow release of the drug. 
This was attributed to gel structure and the surface active 




Diclofenac sodium SLN were prepared by hot 
homogenization method and successfully incorporated 
into carbopol gel for topical delivery. The drug 
permeated from the rat skin. Gels enriched with SLN 
possessed a sustained drug release over period of 24 h. 
Topical administration of DSSLN gel demonstrated 
sustained systemic delivery of the drug. It shows good 
anti-inflammatory activity upto 24 h, in comparison to 
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